ParenteralDosed ingredient Cosmetic cross-reference

Potassium Phosphate, Dibasic

CAS 7758-11-4

Potassium Phosphate, Dibasic (CAS 7758-11-4) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 20 adverse event associations.

SOURCE NLM DailyMed
Label records
1
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
20
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Potassium Phosphate, Dibasic
CAS Number
7758-11-4
UNII
CI71S98N1Z
InChIKey
ZPWVASYFFYYZEW-UHFFFAOYSA-L
ChEMBL ID
CHEMBL1200459
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
DIBASIC POTASSIUM PHOSPHATEPHOSPHATE ION
dosed ingredientparenteral
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1200459 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE NLM DailyMed 1 label row

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

ProductIngredient Active MoietyEffective
Calm DIBASIC POTASSIUM PHOSPHATE
CI71S98N1Z
 PHOSPHATE ION 20260505
SOURCE DrugCentral 15 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Sleep disorder 126 244.7 10040984
Infection 131 129.179 10021789
Product use issue 120 120.531 10076309
Treatment failure 100 97.499 10066901
Rash 160 79.82 10037844
Myocardial reperfusion injury 7 41.273 10051624
Toxic epidermal necrolysis 29 40.463 10044223
Cytokine release syndrome 25 37.032 10052015
Contraindicated product administered 57 30.634 10078504
Joint stiffness 25 28.784 10023230
Malignant neoplasm progression 42 27.229 10051398
Apallic syndrome 7 24.951 10002941
Blood phosphorus decreased 11 23.114 10049471
Product use in unapproved indication 57 22.757 10076476
Skin lesion 21 21.189 10040882

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
POTASSIUM PHOSPHATE, DIBASIC 55018 SU MTHSPL
Potassium Phosphate, Dibasic 55018 SU MTHSPL
potassium phosphate, dibasic 55018 SU MTHSPL
DIBASIC POTASSIUM PHOSPHATE 55018 SU MTHSPL
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Potassium Phosphate, Dibasic used for in pharmaceutical contexts?

Potassium Phosphate, Dibasic (CAS 7758-11-4) appears in DailyMed active-ingredient label rows, including Calm.

What are the known adverse events for Potassium Phosphate, Dibasic?

Potassium Phosphate, Dibasic has 20 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Sleep disorder, Infection, Product use issue, Treatment failure, Rash. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Potassium Phosphate, Dibasic also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Dipotassium Phosphate with EU status "permitted".

What clinical phase is Potassium Phosphate, Dibasic in?

Potassium Phosphate, Dibasic is rendered with ChEMBL max phase 4 (approved).